Tuesday, May 11, 2021

Comments by enochsvision

Showing 2 of 2 comments.

  • “Affluenza” is about to enter the Psychiatrist’s Diagnostics and Standards Manual (DSM-5). It will appear in a special revision of the DSM-5 as soon as trials of the new drug to combat the awful scourge of Affluenza begin. Competing Pharma giants are rushing to market their versions first. One drug will sell under the name of Fallacyia and another will be called Malarkeyum. A third proposed name was Speciousum but research suggested that most doctors couldn’t spell it.

    An eventual generic will simply be named Bunkum.

    Needless to say, the polar opposite of Affluenza is already being exploited in TV commercials as Low-D, as in “Do you suffer from Low-D?” JP Morgan Chase, Citi, Goldman Sachs, and Bank of America appear to be behind the massive push to promote Low-D.